ArticleBMC infectious diseases2026
Pathogen distribution characteristics and risk factors of pulmonary infection associated with immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer: a case control study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo investigate the pathogen distribution and risk factors for pulmonary infection (PI) in patients with advanced non- small cell lung cancer (NSCLC) treated with chemotherapy combined with immune checkpoint inhibitors (ICIs).
methodsPatients with advanced NSCLC who met the inclusion criteria were collected and divided into three groups: chemotherapy with PI group, chemotherapy combined with ICIs with PI group and chemotherapy combined with ICIs without PI group. We displayed the pathogen distribution and infection time of PI for different groups, and explored the risk factors for PI in chemotherapy combined with ICIs group of patients.
resultsA total of 239 patients were included in the study, among which there were 30 cases in the chemotherapy with PI group, 68 cases in the chemotherapy combined with ICIs with PI group, and 141 cases in the chemotherapy combined with ICIs without PI group. The results revealed an increased bacterial infection rate of patients in the chemotherapy with PI group (p = 0.003). Data analysis of patients with combined fungal infections showed a statistically significant difference in the incidence of fungal infections between the two groups (Fisher's exact test, p = 0.035). Multivariate logistic regression analysis revealed that low lymphocyte (LYM) counts (P = 0.016) and stage IV disease (P = 0.012) were independent risk factors for patients in the chemotherapy combined with ICIs with PI group, and number of immunotherapy cycles ≥ 5 (P = 0.031) was associated with a reduced likelihood of PI.
conclusionsIn this observational study, bacterial infections were more common with chemotherapy alone, whereas fungal infections predominated in patients receiving chemotherapy plus ICIs. Low lymphocyte count and stage IV disease were associated with higher pulmonary infection risk, while ≥ 5 cycles of immunotherapy was associated with lower risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.